View Item 

Show simple item record

Anticoagulation of cancer patients with nonâ valvular atrial fibrillation receiving chemotherapy: Guidance from the SSC of the ISTH
dc.contributor.authorDelluc, Aurelien
dc.contributor.authorWang, Tzu‐fei
dc.contributor.authorYap, Eng‐soo
dc.contributor.authorAy, Cihan
dc.contributor.authorSchaefer, Jordan
dc.contributor.authorCarrier, Marc
dc.contributor.authorNoble, Simon
dc.date.accessioned2019-08-09T17:15:17Z
dc.date.availableWITHHELD_13_MONTHS
dc.date.available2019-08-09T17:15:17Z
dc.date.issued2019-08
dc.identifier.citationDelluc, Aurelien; Wang, Tzu‐fei ; Yap, Eng‐soo ; Ay, Cihan; Schaefer, Jordan; Carrier, Marc; Noble, Simon (2019). "Anticoagulation of cancer patients with nonâ valvular atrial fibrillation receiving chemotherapy: Guidance from the SSC of the ISTH." Journal of Thrombosis and Haemostasis 17(8): 1247-1252.
dc.identifier.issn1538-7933
dc.identifier.issn1538-7836
dc.identifier.urihttps://hdl.handle.net/2027.42/150593
dc.publisherWiley Periodicals, Inc.
dc.titleAnticoagulation of cancer patients with nonâ valvular atrial fibrillation receiving chemotherapy: Guidance from the SSC of the ISTH
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelInternal Medicine and Specialties
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/150593/1/jth14478.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/150593/2/jth14478_am.pdf
dc.identifier.doi10.1111/jth.14478
dc.identifier.sourceJournal of Thrombosis and Haemostasis
dc.identifier.citedreferenceShah S, Norby FL, Datta YH, Lutsey PL, MacLehose RF, Chen LY, et al. Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation. Blood Adv. 2018; 2 ( 3 ): 200 â 9.
dc.identifier.citedreferenceNoble SI, Finlay IG. Is longâ term lowâ molecularâ weight heparin acceptable to palliative care patients in the treatment of cancer related venous thromboembolism? A qualitative study. Palliat Med. 2005; 19 ( 3 ): 197 â 201.
dc.identifier.citedreferenceConnolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361 ( 12 ): 1139 â 51.
dc.identifier.citedreferenceGiugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013; 369 ( 22 ): 2093 â 104.
dc.identifier.citedreferenceGranger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365 ( 11 ): 981 â 92.
dc.identifier.citedreferencePatel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365 ( 10 ): 883 â 91.
dc.identifier.citedreferenceRuff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a metaâ analysis of randomised trials. Lancet. 2014; 383 ( 9921 ): 955 â 62.
dc.identifier.citedreferenceChen ST, Hellkamp AS, Becker RC, Berkowitz SD, Breithardt G, Fox KAA, et al. Efficacy and safety of rivaroxaban versus warfarin in patients with Nonvalvular atrial fibrillation and a history of cancer: observations from ROCKET AF. Eur Heart J Qual Care Clin Outcomes. 2019; 5 ( 2 ): 145 â 52.
dc.identifier.citedreferenceMelloni C, Dunning A, Granger CB, Thomas L, Khouri MG, Garcia DA, et al. Efficacy and safety of apixaban versus warfarin in patients with atrial fibrillation and a history of cancer: insights from the ARISTOTLE trial. Am J Med. 2017; 130 ( 12 ): 1440 â 8.e1.
dc.identifier.citedreferenceFanola CL, Ruff CT, Murphy SA, Jin J, Duggal A, Babilonia NA, et al. Efficacy and safety of edoxaban in patients with active malignancy and atrial fibrillation: analysis of the ENGAGE AFâ TIMI 48 trial. J Am Heart Assoc. 2018; 7 ( 16 ): e008987.
dc.identifier.citedreferenceRaskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D, et al. Edoxaban for the treatment of cancerâ associated venous thromboembolism. N Engl J Med. 2018; 378 ( 7 ): 615 â 24.
dc.identifier.citedreferenceYoung AM, Marshall A, Thirlwall J, Chapman O, Lokare A, Hill C, et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECTâ D). J Clin Oncol. 2018; 36: 2017 â 23.
dc.identifier.citedreferenceKhorana AA, Noble S, Lee AYY, Soff G, Meyer G, O’Connell C, et al. Role of direct oral anticoagulants in the treatment of cancerâ associated venous thromboembolism: guidance from the SSC of the ISTH. J Thromb Haemost. 2018; 16: 1891 â 4.
dc.identifier.citedreferenceSteinberg BA, Peterson ED, Kim S, Thomas L, Gersh BJ, Fonarow GC, et al. Use and outcomes associated with bridging during anticoagulation interruptions in patients with atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBITâ AF). Circulation. 2015; 131 ( 5 ): 488 â 94.
dc.identifier.citedreferenceDouketis JD, Spyropoulos AC, Kaatz S, Becker RC, Caprini JA, Dunn AS, et al. Perioperative bridging anticoagulation in patients with atrial fibrillation. N Engl J Med. 2015; 373 ( 9 ): 823 â 33.
dc.identifier.citedreferenceVedovati MC, Giustozzi M, Verdecchia P, Pierpaoli L, Conti S, Verso M, et al. Patients with cancer and atrial fibrillation treated with doacs: a prospective cohort study. Int J Cardiol. 2018; 269: 152 â 7.
dc.identifier.citedreferenceNoble S, Matzdorff A, Maraveyas A, Holm MV, Pisa G. Assessing patientsâ anticoagulation preferences for the treatment of cancerâ associated thrombosis using conjoint methodology. Haematologica. 2015; 100 ( 11 ): 1486 â 92.
dc.identifier.citedreferenceNoble S, Prout H, Nelson A. Patientsâ Experiences of LIving with CANcerâ associated thrombosis: the PELICAN study. Patient Prefer Adherence. 2015; 9: 337 â 45.
dc.identifier.citedreferenceSeaman S, Nelson A, Noble S. Cancerâ associated thrombosis, lowâ molecularâ weight heparin, and the patient experience: a qualitative study. Patient Prefer Adherence. 2014; 8: 453 â 61.
dc.identifier.citedreferencePartridge AH, Burstein HJ, Winer EP. Side effects of chemotherapy and combined chemohormonal therapy in women with earlyâ stage breast cancer. J Natl Cancer Inst Monogr. 2001; 30: 135 â 42.
dc.identifier.citedreferenceChovanec M, Hanna N, Cary KC, Einhorn L, Albany C. Management of stage I testicular germ cell tumours. Nat Rev Urol. 2016; 13 ( 11 ): 663 â 73.
dc.identifier.citedreferenceTufano A, Galderisi M, Esposito L, Trimarco V, Sorriento D, Gerusalem G, et al. Anticancer drugâ related Nonvalvular atrial fibrillation: challenges in management and antithrombotic strategies. Semin Thromb Hemost. 2018; 44 ( 4 ): 388 â 96.
dc.identifier.citedreferenceFlegel KM, Shipley MJ, Rose G. Risk of stroke in nonâ rheumatic atrial fibrillation. Lancet. 1987; 1 ( 8532 ): 526 â 9.
dc.identifier.citedreferenceWolf PA, Dawber TR, Thomas HE Jr, Kannel WB. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study. Neurology. 1978; 28 ( 10 ): 973 â 7.
dc.identifier.citedreferenceJohnstone C, Rich SE. Bleeding in cancer patients and its treatment: a review. Ann Palliat Med. 2018; 7 ( 2 ): 265 â 73.
dc.identifier.citedreferenceAvvisati G, Tirindelli MC, Annibali O. Thrombocytopenia and hemorrhagic risk in cancer patients. Crit Rev Oncol Hematol. 2003; 48 ( Suppl ): S13 â 6.
dc.identifier.citedreferenceMiller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016; 66 ( 4 ): 271 â 89.
dc.identifier.citedreferenceShatzel JJ, Olson SR, Tao DL, McCarty OJT, Danilov AV, DeLoughery TG. Ibrutinibâ associated bleeding: pathogenesis, management and risk reduction strategies. J Thromb Haemost. 2017; 15 ( 5 ): 835 â 47.
dc.identifier.citedreferenceTullemans BME, Heemskerk JWM, Kuijpers MJE. Acquired platelet antagonism: offâ target antiplatelet effects of malignancy treatment with tyrosine kinase inhibitors. J Thromb Haemost. 2018; 16 ( 9 ): 1686 â 99.
dc.identifier.citedreferenceWang SY, Long JB, Hurria A, Owusu C, Steingart RM, Gross CP, et al. Cardiovascular events, early discontinuation of trastuzumab, and their impact on survival. Breast Cancer Res Treat. 2014; 146 ( 2 ): 411 â 9.
dc.identifier.citedreferenceBrown JR, Moslehi J, O’Brien S, Ghia P, Hillmen P, Cymbalista F, et al. Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. Haematologica. 2017; 102 ( 10 ): 1796 â 805.
dc.identifier.citedreferenceWiczer TE, Levine LB, Brumbaugh J, Coggins J, Zhao Q, Ruppert AS, et al. Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib. Blood Adv. 2017; 1 ( 20 ): 1739 â 48.
dc.identifier.citedreferenceHu YF, Liu CJ, Chang PM, Tsao HM, Lin YJ, Chang SL, et al. Incident thromboembolism and heart failure associated with newâ onset atrial fibrillation in cancer patients. Int J Cardiol. 2013; 165 ( 2 ): 355 â 7.
dc.identifier.citedreferenceGage BF, Yan Y, Milligan PE, Waterman AD, Culverhouse R, Rich MW, et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J. 2006; 151 ( 3 ): 713 â 9.
dc.identifier.citedreferencePisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel userâ friendly score (HASâ BLED) to assess 1â year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010; 138 ( 5 ): 1093 â 100.
dc.identifier.citedreferenceD’Souza M, Carlson N, Fosbol E, Lamberts M, Smedegaard L, Nielsen D, et al. CHA2DS2â VASc score and risk of thromboembolism and bleeding in patients with atrial fibrillation and recent cancer. Eur J Prev Cardiol. 2018; 25 ( 6 ): 651 â 8.
dc.identifier.citedreferenceTafur AJ, McBane R 2nd, Wysokinski WE, Litin S, Daniels P, Slusser J, et al. Predictors of major bleeding in periâ procedural anticoagulation management. J Thromb Haemost. 2012; 10 ( 2 ): 261 â 7.
dc.identifier.citedreferenceNavi BB, Reiner AS, Kamel H, Iadecola C, Okin PM, Elkind MSV, et al. Risk of arterial thromboembolism in patients with cancer. J Am Coll Cardiol. 2017; 70 ( 8 ): 926 â 38.
dc.identifier.citedreferenceNavi BB, Reiner AS, Kamel H, Iadecola C, Elkind MS, Panageas KS, et al. Association between incident cancer and subsequent stroke. Ann Neurol. 2015; 77 ( 2 ): 291 â 300.
dc.identifier.citedreferenceHart RG, Pearce LA, Aguilar MI. Metaâ analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007; 146 ( 12 ): 857 â 67.
dc.identifier.citedreferenceHutten BA, Prins MH, Gent M, Ginsberg J, Tijssen JG, Buller HR. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol. 2000; 18 ( 17 ): 3078 â 83.
dc.identifier.citedreferenceRose AJ, Hylek EM, Ozonoff A, Ash AS, Reisman JI, Berlowitz DR. Patient characteristics associated with oral anticoagulation control: results of the Veterans AffaiRs Study to Improve Anticoagulation (VARIA). J Thromb Haemost. 2010; 8 ( 10 ): 2182 â 91.
dc.identifier.citedreferenceRose AJ, Sharman JP, Ozonoff A, Henault LE, Hylek EM. Effectiveness of warfarin among patients with cancer. J Gen Intern Med. 2007; 22 ( 7 ): 997 â 1002.
dc.identifier.citedreferenceAmbrus DB, Reisman JI, Rose AJ. The impact of newâ onset cancer among veterans who are receiving warfarin for atrial fibrillation and venous thromboembolism. Thromb Res. 2016; 144: 21 â 6.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
jth14478.pdf
Size:
476.6KB
Format:
PDF
View/Open
Name:
jth14478_am.pdf
Size:
197.5KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.